You searched for Parkinson's - Page 15 of 20

Best in Biotech 22 Aug 2024

Seven companies transforming the biotech industry in Italy

…such as certain cancers and neurodegenerative diseases like Huntington’s and Parkinson’s. The Italian biotech’s pipeline includes several FID-based candidates targeting various therapeutic areas but its pipeline is still preclinical. Its…

August 22, 2024 - 9 minutesmins - By Jules Adam

Best in Biotech 6 Oct 2022

15 biotech companies shaking up the scene in Cambridge

…and Parkinson’s disease. The company currently has six programs in its pipeline, four in-house programs in research and preclinical phases and two undisclosed partnered programs with AbbVie and Pfizer. Last…

October 6, 2022 - 9 minutesmins - By Helen Albert

In Depth 29 May 2018

Clinical Trials in Alzheimer’s Disease Are Failing: What Can Be Done?

…mental illnesses as well as neurodegenerative disorders such as Parkinson’s and Alzheimer’s. Closely linked with the microbiome is research into metabolism. “This is not yet an area sufficiently mainstream, but…

May 29, 2018 - 6 minutesmins - By Clara Rodríguez Fernández

Startup Scout 10 May 2019

This Biotech Destroys Cancer Proteins by Introducing Them to ‘Executioner’ Proteins

…on the case, discovering new leads that could degrade proteins involved in Alzheimer’s and Parkinson’s disease. Sandham told me that Polyprox could enter the neurodegenerative disease space with a potential…

May 10, 2019 - 4 minutesmins - By Jonathan Smith

biotech stock price euronext genmab argenx

News and Trends 25 May 2021

Delayed IPOs and Market Drops Batter Biotech Stocks

…the Netherlands and bluebird bio in the US, gene therapy trials were paused to investigate cancer cases in a few patients. A trial of a Parkinson’s disease gene therapy developed…

May 25, 2021 - 6 minutesmins - By Jonathan Smith

som biotech huntingtons disease repurpose amyloidosis

Startup Scout 29 Mar 2019

This Biotech Repurposes Drugs to Fight Huntington’s Disease

…Benevolent AI repurposing treatments for Parkinson’s disease. However, Insa told me that SOM Biotech’s technology is three times better at predicting suitable drugs than competitor companies. The company identified an…

March 29, 2019 - 4 minutesmins - By Jonathan Smith

News and Trends 2 Apr 2025

Top biotech deals of March 2025

…together to boost the phase 3 trials of the latter’s AAV-GAD program for Parkinson’s disease. MeiraGTx will bank $200 million upfront. The two will form a joint venture, Hologen Neuro…

April 2, 2025 - 9 minutesmins - By Roohi Mariam Peter

News and Trends 10 Sep 2021

The Top European Biotech Funding Rounds in August

…metabolic diseases involving the liver. And NRG Therapeutics in the UK closed a small seed investment of around £490,000 (€570,000) in a bid to treat Parkinson’s disease. One interesting seed…

September 10, 2021 - 4 minutesmins - By Jonathan Smith

In Depth 7 Mar 2024

Can AbbVie’s legacy live beyond its once best-selling drug Humira?

…Cerevel Therapeutics, a biotech focused on developing drugs to treat psychiatric and neurological disorders. However, the deal with Cerevel has spurred antitrust scrutiny as the latter has Parkinson’s and schizophrenia…

March 7, 2024 - 8 minutesmins - By Roohi Mariam Peter

Best in Biotech 22 Feb 2024

10 gene therapy companies you should know about

…sclerosis, Parkinson’s disease, and various other CNS diseases. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) AAV capsid discovery platform,…

February 22, 2024 - 13 minutesmins - By Willow Shah-Neville

News and Trends 17 Jul 2017

A Brand New Outlook on Induced Pluripotent Stem Cells

…or dopaminergic neurons in the case of Parkinson’s disease. These cells shall then be transplanted into patients to replace their own cells that might be defective, reduced in number, or…

July 17, 2017 - 8 minutesmins - By External Contributor

News and Trends 13 Aug 2019

AskBio Acquires Scottish Biotech to Make Gene Therapies More Precise

…the pipeline, including a phase I/II gene therapy for Parkinson’s disease, and another in phase I/II for the rare neuromuscular disease Pompe disease. Synpromics also has ongoing partnerships with big…

August 13, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Parkinson's

Seven companies transforming the biotech industry in Italy

15 biotech companies shaking up the scene in Cambridge

Clinical Trials in Alzheimer’s Disease Are Failing: What Can Be Done?

This Biotech Destroys Cancer Proteins by Introducing Them to ‘Executioner’ Proteins

Delayed IPOs and Market Drops Batter Biotech Stocks

This Biotech Repurposes Drugs to Fight Huntington’s Disease

Top biotech deals of March 2025

The Top European Biotech Funding Rounds in August

Can AbbVie’s legacy live beyond its once best-selling drug Humira?

10 gene therapy companies you should know about

A Brand New Outlook on Induced Pluripotent Stem Cells

AskBio Acquires Scottish Biotech to Make Gene Therapies More Precise

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!